MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3332/ecancer.2025.1963

Медицинская библиотека · Ecancermedicalscience · 2025

Evaluating Ki-67 and PR as prognostic indicators in CDK4/6 inhibitor treatment for metastatic breast cancer.

Illia María Florencia, Colucci Giuliana, Ballester Angeles, Eiben Mariana, Paesani Fernando, Von Stecher Francisco, de la Vega Máximo, Perazzo Florencia, Mandó Pablo

СтатьяПеревод в очереди

Аннотация

BACKGROUND

The treatment of choice as the first line for patients with metastatic breast cancer (MBC) who are hormone receptor-positive (HR+)/HER2-negative (HER2-) is the combination of endocrine therapy (ET) with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). Identifying prognostic or predictive factors of response could have important clinical implications. This study analysed the prognostic value of Ki-67 and progesterone receptor (PR) expression on progression-free survival (PFS) in this population.

METHODS

A retrospective cohort study was conducted in patients with HR+/HER2- MBC, who had received first-line treatment with CDK4/6i combined with ET. For the PFS analysis, the log-rank test was used and for the multivariate analysis, a Cox regression analysis was performed.

RESULTS

A total of 155 patients were analysed. Patients with PR values <20% showed a trend in univariate analysis towards shorter PFS, with a median of 20.7 months compared to those with a value ≥20%, with a median PFS of 33.0 months (p = 0.090). The Ki-67 value showed no statistically significant association with PFS. The prognostic role of PR was confirmed in the multivariate analysis with an HR of 0.59 (95% CI 0.36-0.98, p = 0.041) in patients with PR >20%.

CONCLUSION

Patients with PR values <20% tended to have shorter PFS, unlike the Ki-67 value, which did not demonstrate an impact on PFS. This suggests a prognostic value of PR expression levels in this scenario.

Для цитирования: Illia María Florencia, Colucci Giuliana, Ballester Angeles, Eiben Mariana, Paesani Fernando, Von Stecher Francisco, de la Vega Máximo, Perazzo Florencia, Mandó Pablo. Evaluating Ki-67 and PR as prognostic indicators in CDK4/6 inhibitor treatment for metastatic breast cancer.. Ecancermedicalscience. 2025. DOI: 10.3332/ecancer.2025.1963.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.